| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11179402 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Apr, 2026
(1 year, 11 months from now) | |
| US10617696 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(2 years from now) | |
| US8241664 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Mar, 2029
(4 years from now) | |
| US10543219 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11426416 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11179403 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8778916 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8492369 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(6 years from now) | |
| US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(14 years from now) | |
Jatenzo is owned by Tolmar.
Jatenzo contains Testosterone Undecanoate.
Jatenzo has a total of 10 drug patents out of which 0 drug patents have expired.
Jatenzo was authorised for market use on 27 March, 2019.
Jatenzo is available in capsule;oral dosage forms.
Jatenzo can be used as a method of treating testosterone deficiency in men, testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, method of treating testosterone deficiency.
The generics of Jatenzo are possible to be released after 12 April, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men; Testosterone replacement therapy in males for conditions associated with a deficiency or absence of end...
Dosage: CAPSULE;ORAL
JATENZO family patents
